Abstract
Leptomeningeal Carcinomatosis (LC) refers to diffuse seeding of the leptomeninges by tumor metastases and is a rare presentation of solid tumors, particularly breast cancer, lung cancer and malignant melanoma in adults and hematogenous malignancies and primitive neuroectodermal tumor (PNET) in children. Recently, the incidence of LC has been reported to be increasing due to a longer overall survival obtained in patients treated with novel antineoplastic agents. The usual clinical presentation is a multifocal involvement of the neuraxis, with headache and radicular pain being the most common initial symptoms. The most frequent signs are motor deficits, altered mental status and cranial nerve involvement. The treatment of LC remains controversial and no straightforward guidelines exist in the literature. It has a bad prognosis and inevitably fatal outcome despite aggressive therapy.
Keywords: Leptomeningeal carcinomatosis, systemic therapy, intrathecal therapy, chemotherapy, radioterapy, methotrexate, capecitabine, temozolamide, ccnu, bcnu, thiotepa, ara-c, lung cancer, breast cancer, erlotinib, gefitinib, Ommaya, liposomal cytarabine, mafosfamide, topotecan, bevacizumab, medulloblastoma, DepoCyt, MRI, leukemia, CSF cytology
Central Nervous System Agents in Medicinal Chemistry
Title: Newer Avenues for the Treatment of Leptomeningeal Carcinomatosis
Volume: 11 Issue: 1
Author(s): Fausto Meriggi and Alberto Zaniboni
Affiliation:
Keywords: Leptomeningeal carcinomatosis, systemic therapy, intrathecal therapy, chemotherapy, radioterapy, methotrexate, capecitabine, temozolamide, ccnu, bcnu, thiotepa, ara-c, lung cancer, breast cancer, erlotinib, gefitinib, Ommaya, liposomal cytarabine, mafosfamide, topotecan, bevacizumab, medulloblastoma, DepoCyt, MRI, leukemia, CSF cytology
Abstract: Leptomeningeal Carcinomatosis (LC) refers to diffuse seeding of the leptomeninges by tumor metastases and is a rare presentation of solid tumors, particularly breast cancer, lung cancer and malignant melanoma in adults and hematogenous malignancies and primitive neuroectodermal tumor (PNET) in children. Recently, the incidence of LC has been reported to be increasing due to a longer overall survival obtained in patients treated with novel antineoplastic agents. The usual clinical presentation is a multifocal involvement of the neuraxis, with headache and radicular pain being the most common initial symptoms. The most frequent signs are motor deficits, altered mental status and cranial nerve involvement. The treatment of LC remains controversial and no straightforward guidelines exist in the literature. It has a bad prognosis and inevitably fatal outcome despite aggressive therapy.
Export Options
About this article
Cite this article as:
Meriggi Fausto and Zaniboni Alberto, Newer Avenues for the Treatment of Leptomeningeal Carcinomatosis, Central Nervous System Agents in Medicinal Chemistry 2011; 11 (1) . https://dx.doi.org/10.2174/187152411794961068
DOI https://dx.doi.org/10.2174/187152411794961068 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Non Smoking for Successful Aging: Therapeutic Perspectives
Current Pharmaceutical Design Helper T Cells Point the Way to Specific Immunotherapy for Autoimmune Disease
Cardiovascular & Hematological Disorders-Drug Targets Interaction Between DNA/histone Methyltransferases and their Inhibitors
Current Medicinal Chemistry False Positive of <sup>68</sup>Ga-DOTATATE PET-CT in a Paraganglioma
Endocrine, Metabolic & Immune Disorders - Drug Targets PET Radioligands for In Vivo Visualization of Neuroinflammation
Current Pharmaceutical Design In vitro activity and Cytotoxicity of Crocus sativus Extract against Leihmania Major (MRHO/IR/75/ER)
Infectious Disorders - Drug Targets Metabolite Identification in NMR-based Metabolomics
Current Metabolomics Potential Role of PKC Inhibitors in the Treatment of Hematological Malignancies
Current Pharmaceutical Design Nanomedicines Based Drug Delivery Systems for Anti-Cancer Targeting and Treatment
Current Drug Delivery Role of Iodine, Selenium and Other Micronutrients in Thyroid Function and Disorders
Endocrine, Metabolic & Immune Disorders - Drug Targets From Protein-Protein Interactions to Rational Drug Design: Are Computational Methods Up to the Challenge?
Current Topics in Medicinal Chemistry In Silico Machine Learning Methods in Drug Development
Current Topics in Medicinal Chemistry Genetics of Serotonin Receptors and Depression: State of the Art
Current Drug Targets Influence of PEG Molecular Weight on the Drug Release and In vitro Cytotoxicity of Single-Walled Carbon Nanotubes-PEG-Gemcitabine Conjugates
Current Drug Delivery Molecular Targets of FTY720 (Fingolimod)
Current Molecular Medicine Biological Activities of Eco-Friendly Synthesized Hantzsch Adducts
Medicinal Chemistry Update of Targeted Therapy-Induced Hypertension: Basics for Non-Oncology Providers
Current Hypertension Reviews The STAT3 Inhibitor Stattic Impairs Cardiomyocyte Mitochondrial Function Through Increased Reactive Oxygen Species Formation
Current Pharmaceutical Design Radioimmunotherapy of Solid Tumors: Searching for the Right Target
Current Drug Delivery Pharmacogenomics of the Human ATP-Binding Cassette Transporter ABCG2
Current Pharmacogenomics